Results: Population 1: The 135 subjects were, on average, 60.73 years old and had a BMI of 32.77 kg/m 2 . The median minimum JSW at inclusion was 3.58 mm (min: 0.30 mm-max: 5.99 mm). After 16 and 30 months followup, the minimum JSW were 3.38 mm (min: 0 mm-max: 5.80 mm) and 2.96 mm (min: 0 mm-max: 5.99 mm), respectively. At 30 months followup, linear regression analysis showed that 85% of the subjects had experienced a JSW decrease. After 30 months, 61 patients (45.2%) were radiographic progressors. By logistic regression, we observed that patients with an increase of uColl2-1NO 2 over 16 months (> 0.052 nmol/mmol Cr) had a high probability (82%) of being radiographic progressors (p<0.001). By contrast, patients with a decrease of uColl2-1NO 2 over 16 months (a decrease more than 0.114 nmol/mmol Cr) had a high probability (80%) of being nonprogressors (p<0.01). Population 2: The 182 women were, on average, 53.54 years old and had a BMI of 35.88 kg/m 2 . The median minimum JSW at inclusion was 3.67 mm (min: 0.57 mm-max: 7.21 mm). After 18 and 30 months, the minimum JSW was 3.59 mm (min: 0 mm -max: 6.60 mm) and 3.54 mm (0 mm-6.49 mm), respectively. Linear regression analysis showed that 64% of subjects experienced a decrease of JSW over 30 months. Among this population, 124 patients (68%) were radiographic nonprogressors while 58 patients (32%) were radiographic progressors. At baseline, uColl2-1NO 2 concentration was 1.25 times higher (p<0.01) in radiographic progressor patients (median: 0.0254 nmol/mmol Cr; min: 0.0073 -max: 0.1890 nmol/mmol Cr) compared to the nonprogressor patients (0.0204 nmol/mmol Cr; min: 0.0043 -max: 0.0637 nmol/mmol Cr). By logistic regression in this population, patients with a high uColl2-1NO 2 concentration at baseline (i.e. 0.172 nmol/mmol Cr) had a high probability (98%) of being radiographic progressors (p<0.001). Also patients with an increase ( 0.0362 nmol/ mmol Cr) of uColl2-1NO 2 over 16 months had a high probability (92%) of being radiographic progressors. Conclusions: The results of the both studies agree well and show a consistent capability of urinary Coll2-1NO 2 to predict knee OA progression. Specifically, the 16-month change in urinary Coll2-1NO 2 is a useful predictor of radiographic progression of knee OA over 30 months in two independent populations totaling a sample size of 317 patients.
Results: Population 1: The 135 subjects were, on average, 60.73 years old and had a BMI of 32.77 kg/m 2 . The median minimum JSW at inclusion was 3.58 mm (min: 0.30 mm-max: 5.99 mm). After 16 and 30 months followup, the minimum JSW were 3.38 mm (min: 0 mm-max: 5.80 mm) and 2.96 mm (min: 0 mm-max: 5.99 mm), respectively. At 30 months followup, linear regression analysis showed that 85% of the subjects had experienced a JSW decrease. After 30 months, 61 patients (45.2%) were radiographic progressors. By logistic regression, we observed that patients with an increase of uColl2-1NO 2 over 16 months (> 0.052 nmol/mmol Cr) had a high probability (82%) of being radiographic progressors (p<0.001). By contrast, patients with a decrease of uColl2-1NO 2 over 16 months (a decrease more than 0.114 nmol/mmol Cr) had a high probability (80%) of being nonprogressors (p<0.01). Population 2: The 182 women were, on average, 53.54 years old and had a BMI of 35.88 kg/m 2 . The median minimum JSW at inclusion was 3.67 mm (min: 0.57 mm-max: 7.21 mm). After 18 and 30 months, the minimum JSW was 3.59 mm (min: 0 mm -max: 6.60 mm) and 3.54 mm (0 mm-6.49 mm), respectively. Linear regression analysis showed that 64% of subjects experienced a decrease of JSW over 30 months. Among this population, 124 patients (68%) were radiographic nonprogressors while 58 patients (32%) were radiographic progressors. At baseline, uColl2-1NO 2 concentration was 1.25 times higher (p<0.01) in radiographic progressor patients (median: 0.0254 nmol/mmol Cr; min: 0.0073 -max: 0.1890 nmol/mmol Cr) compared to the nonprogressor patients (0.0204 nmol/mmol Cr; min: 0.0043 -max: 0.0637 nmol/mmol Cr). By logistic regression in this population, patients with a high uColl2-1NO 2 concentration at baseline (i.e. 0.172 nmol/mmol Cr) had a high probability (98%) of being radiographic progressors (p<0.001). Also patients with an increase ( 0.0362 nmol/ mmol Cr) of uColl2-1NO 2 over 16 months had a high probability (92%) of being radiographic progressors. Conclusions: The results of the both studies agree well and show a consistent capability of urinary Coll2-1NO 2 to predict knee OA progression. Specifically, the 16-month change in urinary Coll2-1NO 2 is a useful predictor of radiographic progression of knee OA over 30 months in two independent populations totaling a sample size of 317 patients. Purpose: To investigate whether change in concentrations over time of aggrecanase generated ARGS-aggrecan in synovial fluid (SF ARGS) associates with progression of radiographic knee osteoarthritis (OA) and patientreported outcome in subjects with previous meniscectomy. Methods: We studied 74 subjects whom at first examination were mean (range) 52 (32 to 73) years old and had been meniscectomized 18 (15 to 22) years earlier, with a follow up examination 7.5 (4 to 10) years later. We obtained synovial fluid, patient-reported outcomes, standing tibiofemoral and skyline patellofemoral radiographs at both examinations. We measured SF ARGS by an electrochemiluminescence immunoassay using an anti-aggrecan antibody (AHP0022; Invitrogen) for capture, and a monoclonal anti-ARGS (OA-1) for detection. Radiographic outcomes (loss of joint space, osteophyte progression, and radiographic OA progression) were based on progression from first to second examination of the scores of joint space narrowing (JSN), osteophytes, and either JSN or osteophytes or both, scored according to the OARSI atlas; progression was defined as an increase in the respective scores with one or more. Patient-reported outcomes was assessed by Knee injury and Osteoarthritis Outcome Score (KOOS) with the five dimensions, pain, other symptoms, function of daily living, function in sports and recreation, and knee-related quality of life; progression was defined as a worsening in the respective score by 10 units or more. To study the association between the change in levels of SF ARGS between examinations and progression of radiographic OA and KOOS, we created a dichotomous SF ARGS variable (increase or decrease) and used multivariate logistic regression adjusted for age, gender, body mass index, time between examinations, and SF ARGS at first examination. Results: SF ARGS levels were mean (and range) 6.66 (0.15-14.58) and 7.06 (0.12-14.71) pmol ARGS/ml at first and second examinations respectively, and showed a correlation between examinations (Pearson's correlation coefficient ¼ 0.611, P < 0.001). There was a significant association between decreasing levels of SF ARGS and loss of joint space and worsening of KOOS pain: in subjects with decreasing SF ARGS between examinations, the likelihood of loss of joint space and worsening of KOOS pain between examinations was increased 6-and 4-fold, respectively, compared to those increasing in SF ARGS (Table 1) . No significant associations were seen between decreasing SF ARGS and osteophyte progression, or patientreported outcomes other than KOOS pain. Conclusions: In middle-aged subjects with a meniscectomy 18 years earlier, decreasing levels of SF ARGS over the next four to ten years were associated with an increased risk for loss of joint space and worsening of knee pain over the same time period, but showed no association with other patient-reported outcomes or osteophyte progression. Purpose:: Although many biomarkers are known to have diagnostic and prognostic capacity for knee OA, few of them are reliable enough to be used clinically. Some investigators have attempted to improve the diagnostic performance of biomarkers by measuring two or more biomarkers together, but it has not been known if this strategy is indeed useful or not. In this study, we attempted to know the best possible combinations of biomarkers for knee OA for the diagnosis and the prediction of disease progression. Methods: The study included 43 knee OA patients (mean, 71.7 years), and 30 age matched healthy volunteers (mean, 68.5 years). To be included in the study, an OA patient had to be at least 50 years old, and have medially involved knee OA in at least one of the knee joints. The diagnosis of knee OA was based on the ACR criteria, and the knees with the severest stage of OA (Kellgren-Lawrence grade 4) were excluded from the study because progression of joint space narrowing was not evaluated with such knees. All knee OA patients were followed up for 2 years, during which the patients were asked to visit clinics every 6 months. For these patients, knee radiographs were taken in the weight-bearing fixed-flexion method (Peterfy, 2003) , and blood and urine samples were obtained at each visit. Progression of knee OA was determined on the radiographs, by measuring the narrowest width between the femur and tibia in the medial compartment. Since radiographs were obtained every 6 months, we were able to specify the 6month periods in which the narrowing actually occurred. Blood and urine samples were obtained once from the healthy controls. Fourteen serum biomarkers and 6 urine biomarkers, which have been reported to associate with the pathology of knee OA, were measured with serum and urine samples, respectively (Table) . The markers were compared Abstracts / Osteoarthritis and Cartilage 20 (2012) S54-S296 S81
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